ALPINE IMMUNE SCIENCES, INC. Deferred Revenue Recognized
ALPINE IMMUNE SCIENCES, INC. reported Deferred Revenue Recognized of $7.00 million for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-09.
Discontinued › Income Statement › Other Income
us-gaap:ContractWithCustomerLiabilityRevenueRecognized · last filed 2024-05-09
- ALPINE IMMUNE SCIENCES, INC. contract with customer, liability, revenue recognized for the quarter ending 2024-03-31 was $7.00M, a 20.45% decline year-over-year.
- ALPINE IMMUNE SCIENCES, INC. contract with customer, liability, revenue recognized for the quarter ending 2023-03-31 was $8.80M, a 34.81% decline year-over-year.
- ALPINE IMMUNE SCIENCES, INC. contract with customer, liability, revenue recognized for the quarter ending 2022-06-30 was $5.10M, a 29.17% decline year-over-year.
- ALPINE IMMUNE SCIENCES, INC. contract with customer, liability, revenue recognized for the quarter ending 2022-03-31 was $13.50M, a 321.88% increase year-over-year.
- ALPINE IMMUNE SCIENCES, INC. contract with customer, liability, revenue recognized for fiscal 2022 was $28.20M, a 20.51% increase from fiscal 2021.
- ALPINE IMMUNE SCIENCES, INC. contract with customer, liability, revenue recognized for fiscal 2021 was $23.40M, a 917.39% increase from fiscal 2020.
- ALPINE IMMUNE SCIENCES, INC. contract with customer, liability, revenue recognized for fiscal 2020 was $2.30M.
| Period end | Contract with Customer, Liability, Revenue Recognized 3 month | Contract with Customer, Liability, Revenue Recognized 6 month | Contract with Customer, Liability, Revenue Recognized 9 month | Contract with Customer, Liability, Revenue Recognized 12 month |
|---|---|---|---|---|
| 2024-03-31 | $7.00M 10-Q · filed 2024-05-09 | |||
| 2023-09-30 | $26.90M 10-Q · filed 2023-11-14 | |||
| 2023-06-30 | $17.00M 10-Q · filed 2023-08-14 | |||
| 2023-03-31 | $8.80M 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | $28.20M 10-K · filed 2023-03-23 | |||
| 2022-09-30 | $26.30M 10-Q · filed 2023-11-14 | |||
| 2022-06-30 | $5.10M 10-Q · filed 2022-08-11 | $18.60M 10-Q · filed 2023-08-14 | ||
| 2022-03-31 | $13.50M 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | $23.40M 10-K · filed 2023-03-23 | |||
| 2021-09-30 | $18.90M 10-Q · filed 2022-11-14 | |||
| 2021-06-30 | $7.20M 10-Q · filed 2022-08-11 | $10.40M 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | $3.20M 10-Q · filed 2022-05-12 | |||
| 2020-12-31 | $2.30M 10-K · filed 2023-03-23 |